Drug in adhesive type transdermal matrix systems of ondansetron hydrochloride: Optimization of permeation pattern using response surface methodology

Journal of Drug Targeting

Volumn 18, Issue 2, 2010, Pages 106-114

  Swain, Kalpana ^a   Pattnaik, Satyanarayan ^a   Sahu, Sarat Chandra ^a   Patnaik, Kiran Kumar ^b   Mallick, Subrata ^c  

^a Department of Pharmaceutics   (India)

^b MKCG MEDICAL COLLEGE   (India)

^c SIKSHA O ANUSANDHAN DEEMED TO BE UNIVERSITY   (India)

Author keywords

Ondansetron hydrochloride; Permeation; Permeation enhancer; Transdermal delivery

Indexed keywords

LAURIC ACID; OLEIC ACID; ONDANSETRON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CADAVER; CONTROLLED STUDY; DRUG FORMULATION; DRUG PENETRATION; EX VIVO STUDY; HUMAN; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; RESPONSE SURFACE METHOD; SKIN IRRITATION; SKIN PERMEABILITY;

ADMINISTRATION, CUTANEOUS; ANIMALS; CADAVER; DRUG DELIVERY SYSTEMS; HUMANS; MEMBRANES, ARTIFICIAL; ONDANSETRON; PERMEABILITY; RABBITS; SEROTONIN ANTAGONISTS; SKIN; SURFACE PROPERTIES;

EID: 75149128544     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611860903225727     Document Type: Article

References (32)

1. Barry BW. (2004). Breaching the skin's barrier to drugs. Nat Biotechnol, 22, 165-167
2. Bodea A, Leucuta SE. (1997). Optimization of hydrophilic matrix tablets using a d-optimal design. Int J Pharm, 153, 247-255
3. Bozigian HP, Pritchard JF, Gooding AE, Pakes GE. (1994). Ondansetron absorption in adults: effect of dosage form, food, and antacids. J Pharm Sci, 83, 1011-1013
4. Butcher ME. (1993). Global experience with ondansetron and future potential. Oncology, 50, 191-197
5. Chien YW. (1982). Novel Drug Delivery Systems (pp. 160-161). New York: Marcel Dekker
6. Cho E, Gwak H, Chun I. (2008). Formulation and evaluation of ondansetron nasal delivery systems. Int J Pharm, 349, 101-107
7. Cornell JA. (1990). Designs Models and the Analysis of Mixture Data (pp. 188-236). 2nd ed. New York: John Wiley & Sons
8. Draize JH, Woodard G, Calvery HO. (1944). Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther, 82, 377-390
9. Eriksson L, Johansson E, Wikstrom C. (1998). Mixture design: design generation, PLS analysis and model usage. Chemomet Intell Lab Syst, 43, 1-24
10. Figg WD, Dukes GE, Pritchard JF, Hermann DJ, Lesesne HR, Carson SW, Songer SS, Powell JR, Hak LJ. (1996). Pharmacokinetics of ondansetron in patients with hepatic insufficiency. J Clin Pharmacol, 36, 206-215
11. Fischer W, Stierle A. (2002). Transdermal systems for release of 5-HT3 receptor antagonists and their use in anti-emetic treatment. Novosis Pharma AG assignee, United States Patent no. 6,440,453 B1
12. Funke AP, Gunther C, Muller RH, Lipp R. (2002). In vitro release and transdermal fluxes of a highly lipophilic drug and of enhancers from matrix TDS. J Control Rel, 82, 63-70
13. Gupta SP, Jain S. K. (2006). Transdermal atenolol releasing system: an approach towards its development. J Drug Target, 14, 607-613
14. Gwak HS, Oh SI, Chun KI. (2003). In vitro percutaneous absorption of ondansetron hydrochloride from pressure-sensitive adhesive matrices through hairless mouse skin. Arch Pharm Res, 26, 644-648
15. Hesketh PJ, Gandara DR. (1991). Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst, 83, 613-620
16. Hsyu PH, Pritchard JF, Bozigian HP, Lloyd TL, Griffin RH, Shamburek R, Krishna G, Barr WH. (1994). Comparison of the pharmacokinetics of an ondansetron solution (8 mg) when administered intravenously, orally, to the colon, and to the rectum. Pharm Res, 11, 156-159
17. Hussain AA, Dakkuri A, Itoh S. (2000). Nasal absorption of ondansetron in rats: an alternative route of drug delivery. Cancer Chemother Pharmacol, 45, 432-434
18. Keshary PR, Chien YW. (1984). Mechanism of transdermal controlled nitroglycerin administration. Part 2. Assessment of rate controlling steps. Drug Dev Ind Pharm, 10, 1663-1699
19. Krishna R, Pandit JK. (1994). Transdermal delivery of propranolol. Drug Dev Ind Pharm, 20, 2459-2465
20. Lewis GA, Mathieu D, Phan-Tan-Luu R. (1999). Response surface methodology. In: Pharmaceutical Experimental Design (pp. 185-246). New York: Marcel Dekker Inc
21. McKenzie R, Kovac A, O'Connor T, Duncalf D, Angel J, Gratz I, Tolpin E, McLeskey C, Joslyn A. (1993). Comparison of ondansetron versus placebo to prevent postoperative nausea and vomiting in women undergoing ambulatory gynecologic surgery. Anesthesiology, 78, 21-28
22. Melas VB. (2006). Functional Approach to Optimal Experimental Design (pp. 197-228). New York: Springer
23. Mukherjee B, Mahapatra S, Gupta R, Patra B, Tiwari A, Arora P. (2005). A comparison between povidone-ethylcellulose and povidone-eudragit transdermal dexamethasone matrix patches based on in vitro skin permeation. Eur J Pharm Biopharm, 59, 475-483
24. Myers RH, Montgomery DC. (2002). Response Surface Methodology: Process and Product Optimization Using Designed Experiments (pp. 273-286). New York: John Wiley & Sons
25. Pattnaik S, Swain K, Mallick S. (2009). Influence of polymeric system and loading dose on drug release from alfuzosin hydrochloride transdermal films. Lat Am J Pharm, 28, 62-69
26. Rolia F, Del Favero A. (1995). Ondansetron clinical pharmacokinetics. Clin Pharmacokinet, 29, 95-109
27. Scuderi P, Wetchler B, Sung YF, Mingus M, DuPen S, Claybon L, Leslie J, Talke P, Apfelbaum J, Sharifi-Azad S. (1993). Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron. Anesthesiology, 78, 15-20
28. Sherertz EF, Solan KB, McTiernan RG. (1987). Effect of skin pretreatment with vehicle alone or drug in vehicle on flux of a subsequently applied drug: results of hairless mouse skin and diffusion cell studies. J Invest Dermatol, 89, 249-252
29. Swain K, Pattnaik S, Mallick S, Chowdary KA. (2009). Influence of hydroxypropyl methylcellulose on drug release pattern of a gastroretentive floating drug delivery system using a 32 full factorial design. Pharm Dev Technol, 14, 193-198
30. Tiwary AK, Sapra B, Jain S. (2007) Innovations in transdermal drug delivery: formulations and techniques Recent Pat Drug Deliv Formul, 1, 23-36
31. Yadav AK, Mishra P, Agrawal GP. (2008). Use of microparticulate systems to accelerate skin wound healing: an insight on hyaluronic acid in drug targeting and drug delivery. J Drug Target, 16, 91-107
32. Zhan X, Tang G, Chen S, Mao Z. (2006). A new copolymer membrane controlling clonidine linear release in a transdermal drug delivery system. Int J Pharm, 322, 1-5